Envoy Medical Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Envoy Medical, Inc. engages in designing, developing and marketing fully implantable medical devices that improve hearing. The company was founded in 1995 and is headquartered in White Bear Lake, MN.

Initial patient enrollment anticipated during first quarter of 2025 White Bear Lake, Minnesota--(Newsfile Corp. - December 19, 2024) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company, today announces it has selected seven study sites for participation in its pivotal clinical trial to investigate its fully implanted Acclaim® cochlear implant (Acclaim CI). Initial patient enrollment is anticipated to begin during the first quarter of 2025.

Envoy Medical Names Seven Investigational Sites for Participation in Its Pivotal Clinical Study

FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved fully implanted middle ear implant are two of the exciting developments for the growing company FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved fully implanted middle ear implant are two of the exciting developments for the growing company

Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events

Study in Otology & Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear implant

Envoy Medical's Fully Implanted Acclaim® Cochlear Implant Highlighted in Peer-Reviewed Publication

WHITE BEAR LAKE, Minnesota, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announces that the European Patent Office has granted the Company Patent No. 3858425, titled,” Implantable Modular Cochlear Implant System with Communication System and Network.”

Envoy Medical Receives Another European Patent for its Modular Cochlear Implant System

The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients

Envoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device

WHITE BEAR LAKE, Minnesota, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announced that David R. Wells, Chief Financial Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.

Envoy Medical to Present at the LD Micro Main Event XVII

During “The Claman Countdown,” the billionaire investor and entrepreneur noted how hearing aid modes in next-gen wireless earbuds can work with Envoy Medical's fully implanted hearing devices

Major Envoy Medical Investor Glen Taylor Discusses How Apple's AirPods Pro 2 Hearing Aid Announcement is a Potentially Positive Development for the Company

Growing Portfolio of Patents Further Advances the Company's Mission to Develop Fully Implanted Devices for Those Suffering from Significant Hearing Loss

Envoy Medical Awarded Patent for Recharge System used with Implantable Battery

Hyliion

60 Degrees Pharmaceuticals Inc

The Dow Jones index closed higher by more than 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim ® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year

Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update

Envoy Medical's FDA-Approved Esteem® Fully Implanted Active Middle Ear Hearing Device May Now Have an Opportunity to be a Coverable Benefit

Bipartisan Senate Bill Seeks to Clarify that Implanted Active Middle Ear Hearing Devices are Prosthetics, Not Hearing Aids, Making Them Eligible for Medicare Coverage

WHITE BEAR LAKE, MN, July 01, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that FTSE Russell has selected the Company's shares for inclusion in its Microcap Index. The inclusion became effective at the close of market on Friday, June 28, 2024.

Envoy Medical Announces Inclusion in the Russell Microcap Index

WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024.

Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

WHITE BEAR LAKE, MN, June 06, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that MSCI has selected the Company's shares for inclusion in its MSCI USA Micro Cap Index.  The inclusion became effective at the close of market on Friday, May 31, 2024.  The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised of over 1,100 constituents with an average market cap of $122 million at April 30, 2024.  A wide range of microcap ETFs follow this benchmark and may reweight their holdings over the coming weeks for changes that occurred in this Index effective as of May 31.

Envoy Medical Announces Inclusion in the MSCI USA Micro Cap Index

Envoy Medical is a hearing device company that offers fully implantable devices for people with moderate to severe hearing loss. The company's second device, Acclaim, has been granted Breakthrough Device status and is about to begin clinical trials for FDA approval. Envoy's devices offer advantages such as no external device, no cleaning required, no risk of costly replacement, and 24/7 usage.

Envoy Medical Is Pursuing Filling A Hearing Industry Void

The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant.

Envoy Medical Reports First Quarter 2024 Results

NEW YORK , April 20, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Envoy Medical, Inc. (NASDAQ: COCH) resulting from allegations that Envoy may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Envoy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation - COCH

NEW YORK , April 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Envoy Medical, Inc. (NASDAQ: COCH) resulting from allegations that Envoy may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Envoy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

COCH LOSS ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation - COCH

NEW YORK , April 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Envoy Medical, Inc. (NASDAQ: COCH) resulting from allegations that Envoy may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Envoy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation - COCH

WHITE BEAR LAKE, Minnesota , April 03, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that Brent Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer, will present a corporate overview at the LD Micro Invitational XIV 2024.  The conference is being held on April 8 - 9, 2024 at the Sofitel Hotel in New York City.

Envoy Medical to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Company Provides Corporate Update that Include Updates on its Investigational Fully Implanted Acclaim® Cochlear Implant Meeting its Early Feasibility Study Milestones

Envoy Medical Reports Fourth Quarter and Full Year 2023 Financial Results

NEW YORK , March 24, 2024 /PRNewswire/ -- WHY:  on behalf of shareholders of Envoy Medical, Inc. (NASDAQ: COCH) resulting from allegations that Envoy may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Envoy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation - COCH

NEW YORK , March 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Envoy Medical, Inc. (NASDAQ: COCH) resulting from allegations that Envoy may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Envoy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

COCH INVESTOR ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Envoy Medical, Inc. Investors to Inquire About Securities Class Action Investigation - COCH

WHITE BEAR LAKE, Minnesota, March 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will participate in the 36th Annual ROTH Conference being held on March 17 – 19, 2024 at The Ritz Carlton, Laguna Niguel located in Dana Point, CA.

Envoy Medical to Participate in the 36th Annual ROTH Conference

NEW YORK , March 9, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Envoy Medical, Inc. (NASDAQ: COCH) resulting from allegations that Envoy may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Envoy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

News for Envoy Medical Inc Stock (COCH)